{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"110","value":"363"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"}],"units":"Participants"}],"title":"Cycle 1: Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"176","value":"562"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"title":"Cycle 1: Day 15"}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"}],"units":"Participants"}],"description":"Ceoi is the plasma concentration observed at the end of intravenous infusion of isatuximab.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with AML received isatuximab 20 mg/kg IV infusion on Days 1, 8, and 15 of each Cycle (up to 2 treatment cycles, each cycle 28 days). Participants received recommended isatuximab premedication as per protocol. Starting on Day 8, combination chemotherapies were added. Participants without documented disease progression at EOT visit who had not started treatment with another anticancer therapy received follow-up visits every 2 months until initiation of another anticancer therapy, disease progression, death, or final analysis cut-off date, whichever occurred first. Participants with documented disease progression/initiation of new anticancer treatment were followed for survival every 4 months until death or final analysis cut-off date, whichever occurred first.","id":"OG000","title":"Acute Myeloid Leukemia (AML)"}],"paramType":"MEAN","populationDescription":"The PK population consisted of all participants from the AT population with at least 1 PK parameter available (isatuximab concentration). Only those participants with data available at specified timepoints were analyzed.","reportingStatus":"POSTED","timeFrame":"At end of infusion on Cycle 1 Days 1 and 15","title":"AML: Ceoi of Isatuximab","type":"SECONDARY","unitOfMeasure":"mcg/mL"}